Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Innovative DNA vaccine to break immune tolerance against tumor self-antigen.

Kang TH, Mao CP, La V, Chen A, Hung CF, Wu TC.

Hum Gene Ther. 2013 Feb;24(2):181-8. doi: 10.1089/hum.2012.141. Epub 2013 Jan 30.

2.

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.

3.

Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.

Li L, Herndon JM, Truscott SM, Hansen TH, Fleming TP, Goedegebuure P, Gillanders WE.

Vaccine. 2010 Feb 23;28(8):1911-8. doi: 10.1016/j.vaccine.2009.10.096.

4.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

5.

Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection.

Kim S, Zuiani A, Carrero JA, Hansen TH.

Vaccine. 2012 Mar 9;30(12):2178-86. doi: 10.1016/j.vaccine.2012.01.012. Epub 2012 Jan 26.

6.

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.

Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK.

Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4.

7.
8.

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Chen R, Wang S, Yao Y, Zhou Y, Zhang C, Fang J, Zhang D, Zhang L, Pan J.

Oncol Rep. 2015 May;33(5):2269-76. doi: 10.3892/or.2015.3820. Epub 2015 Feb 26.

PMID:
25739076
9.

Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.

Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA.

Cancer Res. 2001 Aug 15;61(16):6178-84.

10.
11.
12.

Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen.

Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC.

Cancer Res. 2001 May 1;61(9):3698-703.

13.

DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens.

Ordaz ML, Larmonier N, Lybarger L.

Cell Immunol. 2010;262(2):141-9. doi: 10.1016/j.cellimm.2010.02.006. Epub 2010 Feb 10.

PMID:
20199770
14.

DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.

Rice J, Dunn S, Piper K, Buchan SL, Moss PA, Stevenson FK.

Cancer Res. 2006 May 15;66(10):5436-42.

15.

Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.

Qin Y, Wang XH, Cui HL, Cheung YK, Hu MH, Zhu SG, Xie Y.

Gynecol Oncol. 2005 Feb;96(2):475-83.

PMID:
15661238
16.

Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.

Jia ZC, Zou LY, Ni B, Wan Y, Zhou W, Lv YB, Geng M, Wu YZ.

Cancer Immunol Immunother. 2005 May;54(5):446-52. Epub 2004 Nov 16.

PMID:
15750831
17.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
18.
19.

Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope.

Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, Wu TC, Hung CF.

Gene Ther. 2005 Aug;12(15):1180-6.

20.

Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.

Pedersen SR, Sørensen MR, Buus S, Christensen JP, Thomsen AR.

J Immunol. 2013 Oct 1;191(7):3955-67. doi: 10.4049/jimmunol.1300555. Epub 2013 Sep 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk